Broad Institute's CRISPR patent invalidated by JPO over priority rights
South Korean biotech company ToolGen has won a patent-invalidation case in Japan, where Japan’s patent office invalidated a genome-engineering technology patent held by The Broad Institute, the Massachusetts Institute of Technology...To view the full article, register now.
Already a subscriber? Click here to view full article